Gravitational radiation from a particle in circular orbit around a black hole. VI. Accuracy of the post-Newtonian expansion

A particle of mass $\mu$ moves on a circular orbit around a nonrotating black hole of mass $M$. Under the assumption $\mu \ll M$ the gravitational waves emitted by such a binary system can be calculated exactly numerically using black-hole perturbation theory. If, further, the particle is slowly moving, then the waves can be calculated approximately analytically, and expressed in the form of a post-Newtonian expansion. We determine the accuracy of this expansion in a quantitative way by calculating the reduction in signal-to-noise ratio incurred when matched filtering the exact signal with a nonoptimal, post-Newtonian filter.Comment: 5 pages, ReVTeX, 1 figure. A typographical error was discovered in the computer code used to generate the results presented in the paper. The corrected results are presented in an Erratum, which also incorporates new results, obtained using the recently improved post-Newtonian calculations of Tanaka, Tagoshi, and Sasak

Measuring black-hole parameters and testing general relativity using gravitational-wave data from space-based interferometers

Among the expected sources of gravitational waves for the Laser Interferometer Space Antenna (LISA) is the capture of solar-mass compact stars by massive black holes residing in galactic centers. We construct a simple model for such a capture, in which the compact star moves freely on a circular orbit in the equatorial plane of the massive black hole. We consider the gravitational waves emitted during the late stages of orbital evolution, shortly before the orbiting mass reaches the innermost stable circular orbit. We construct a simple model for the gravitational-wave signal, in which the phasing of the waves plays the dominant role. The signal's behavior depends on a number of parameters, including $\mu$, the mass of the orbiting star, $M$, the mass of the central black hole, and $J$, the black hole's angular momentum. We calculate, using our simplified model, and in the limit of large signal-to-noise ratio, the accuracy with which these quantities can be estimated during a gravitational-wave measurement. Our simplified model also suggests a method for experimentally testing the strong-field predictions of general relativity.Comment: ReVTeX, 16 pages, 5 postscript figure

Gravitational waves from inspiralling compact binaries: Parameter estimation using second-post-Newtonian waveforms

The parameters of inspiralling compact binaries can be estimated using matched filtering of gravitational-waveform templates against the output of laser-interferometric gravitational-wave detectors. Using a recently calculated formula, accurate to second post-Newtonian (2PN) order [order $(v/c)^4$, where $v$ is the orbital velocity], for the frequency sweep ($dF/dt$) induced by gravitational radiation damping, we study the statistical errors in the determination of such source parameters as the ``chirp mass'' $\cal M$, reduced mass $\mu$, and spin parameters $\beta$ and $\sigma$ (related to spin-orbit and spin-spin effects, respectively). We find that previous results using template phasing accurate to 1.5PN order actually underestimated the errors in $\cal M$, $\mu$, and $\beta$. For two inspiralling neutron stars, the measurement errors increase by less than 16 percent.Comment: 14 pages, ReVTe

The Sensitivity of Ligo to a Stochastic Background, and its Dependance on the Detector Orientations

We analyze the sensitivity of a network of interferometer gravitational-wave detectors to the gravitational-wave stochastic background, and derive the dependence of this sensitivity on the orientations of the detector arms. We build on and extend the recent work of Christensen, but our conclusion for the optimal choice of orientations of a pair of detectors differs from his. For a pair of detectors (such as LIGO) that subtends an angle at the center of the earth of \,\alt 70^\circ, we find that the optimal configuration is for each detector to have its arms make an angle of $45^\circ$ (modulo $90^\circ$) with the arc of the great circle that joins them. For detectors that are farther separated, each detector should instead have one arm aligned with this arc. We also describe in detail the optimal data-analysis algorithm for searching for the stochastic background with a detector network, which is implicit in earlier work of Michelson. The LIGO pair of detectors will be separated by $\sim 3000 \, {\rm km}$. The minimum detectable stochastic energy-density for these detectors with their currently planned orientations is $\sim 3\%$ greater than what it would be if the orientations were optimal.Comment: 56 pages, 10 figures, Caltech preprint GRP-347, submitted to Phys Rev D, uses revtex macro

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Treatment of recent-onset type 1 diabetic patients with DiaPep277: Results of a double-blind, placebo-controlled, randomized phase 3 trial.

OBJECTIVE: To evaluate safety and efficacy of DiaPep277 in preserving &beta;-cell function in type 1 diabetic patients. RESEARCH DESIGN AND METHODS: DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457, aged 16-45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA1c &le;7% (&le;53 mmol/mol). Partial remission (target HbA1c on insulin &le;0.5 units/kg/day) and hypoglycemic event rate were exploratory end points. RESULTS: DiaPep277 was safe and well tolerated. Significant preservation of C-peptide secretion was observed in the DiaPep277-treated group compared with the placebo (relative treatment effects of 23.4%, P = 0.037, and 29.2%, P = 0.011, in the modified intent-to-treat [mITT] and per-protocol [PP] populations, respectively). The mixed-meal stimulation failed to distinguish between the groups. There was a trend toward efficacy in fasting C-peptide levels, though not statistically significant. Significantly more DiaPep277-treated than placebo-treated patients maintained target HbA1c (mITT 56% versus 44%, P = 0.03; PP 60% versus 45%, P = 0.0082) and entered partial remission (mITT 38% versus 29%, P = 0.08; PP 42% versus 30%, P = 0.035). DiaPep277 treatment reduced the relative hypoglycemic event risk (mITT by 20%; PP by 28%). CONCLUSIONS: DiaPep277 safely contributes to preservation of &beta;-cell function and to improved glycemic control in patients with type 1 diabetes